TNFRSF8 and neoplasm: Lastly, the efficiency of CD30+ tumor cell cytotoxicity was compared for freshly biAb-coated activated T cells versus biAb-coated, cryopreserved and then thawed activated T cells, consistent with anticipated clinical utilization.